Come si colloca il rapporto KDNY di PB rispetto ai suoi colleghi?

KDNY è costoso in base al suo rapporto Price-To-Book ( 8.1 x) rispetto alla media dei peer ( 4.8 x).

Come si colloca il KDNY's PB Ratio rispetto ad altre aziende del US Biotechs settore?

KDNY è costoso in base al suo rapporto Price-To-Book ( 8.1 x) rispetto alla media del settore US Biotechs ( 1.9 x).

Qual è il KDNY PB Ratio rispetto al suo Fair PB Ratio? Si tratta del PB Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

Dati insufficienti per calcolare il Fair Ratio di KDNY Price-To-Book per l'analisi di valutazione.

Qual è il prezzo equo di KDNY se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

Dati insufficienti per calcolare il valore equo di KDNY ai fini dell'analisi di valutazione.

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Il prezzo obiettivo è inferiore al prezzo attuale delle azioni.

Chinook Therapeutics (Nasdaq:KDNY) - Prezzo delle azioni, notizie e analisi

KDNY Panoramica delle azioni

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Maggiori dettagli

KDNY analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 63.8% all'anno

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Gli azionisti sono stati diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Chinook Therapeutics, Inc. Concorrenti

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Janux Therapeutics

NasdaqGM:JANX

US$2.6b

Zai Lab

NasdaqGM:ZLAB

US$2.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Chinook Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$40.39
Massimo di 52 settimane	US$40.51
Minimo di 52 settimane	US$18.34
Beta	0.67
1Variazione di 1 mese	2.98%
Variazione a 3 mesi	72.68%
Variazione di 1 anno	95.69%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	173.46%

Notizie e aggiornamenti recenti

Recent updates

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

May 28

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

Feb 14

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Aug 31

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Aug 12

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Aug 08

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Jul 05

Rendimenti per gli azionisti

	KDNY	US Biotechs	US Mercato
7D	0.3%	4.0%	2.0%
1Y	95.7%	18.0%	32.4%

Ritorno vs Industria: KDNY ha superato il US Biotechs che ha restituito 18 % nell'ultimo anno.

Rendimento vs Mercato: KDNY ha superato il mercato US che ha restituito 32.4 % nell'ultimo anno.

Volatilità dei prezzi

Is KDNY's price volatile compared to industry and market?
KDNY volatility
KDNY Average Weekly Movement	17.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di KDNY è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di KDNY è aumentata da 10% a 17% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	214	Eric Dobmeier	www.chinooktx.com

Chinook Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Chinook Therapeutics con la sua capitalizzazione di mercato?
KDNY statistiche fondamentali
Capitalizzazione di mercato	US$2.90b
Guadagni(TTM)	-US$245.65m
Ricavi(TTM)	US$5.85m

495.8x

Rapporto P/S

-11.8x

Rapporto P/E

KDNY è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
KDNY Conto economico (TTM)
Ricavi	US$5.85m
Costo del fatturato	US$193.72m
Profitto lordo	-US$187.87m
Altre spese	US$57.79m
Guadagni	-US$245.65m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-3.42
Margine lordo	-3,211.95%
Margine di profitto netto	-4,199.93%
Rapporto debito/patrimonio netto	0%

Come si è comportato KDNY nel lungo periodo?

Vedi performance storica e confronto

KDNY Panoramica delle azioni

Premi

Analisi del rischio

Chinook Therapeutics, Inc. Concorrenti

NasdaqCM:CPRX

US$2.5b

NasdaqGS:TPTX

US$3.8b

NasdaqGM:JANX

US$2.6b

NasdaqGM:ZLAB

US$2.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Price target increased by 7.8% to US$39.45

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

New major risk - Share price stability

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

President recently sold US$190k worth of stock

Chief Scientific Officer exercised options and sold US$191k worth of stock

Chief Operating Officer exercised options and sold US$246k worth of stock

President exercised options and sold US$657k worth of stock

Consensus forecasts updated

Chief Operating Officer notifies of intention to sell stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Operating Officer exercised options and sold US$217k worth of stock

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Chief Operating Officer exercised options and sold US$145k worth of stock

Independent Director recently bought US$212k worth of stock

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Consensus revenue estimates fall by 14%

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chief Scientific Officer exercised options and sold US$98k worth of stock

Chief Scientific Officer exercised options and sold US$89k worth of stock

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

High number of new directors

President recently bought US$65k worth of stock

Consensus forecasts updated

Price target increased to US$34.86

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chief Scientific Officer exercised options and sold US$75k worth of stock

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Chinook Therapeutics, Inc. Riepilogo dei fondamenti

495.8x